we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.
Company profile
Ticker
LYEL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
833006753
LYEL stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
6 May 24
10-Q
2024 Q1
Quarterly report
6 May 24
8-K
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
6 May 24
EFFECT
Notice of effectiveness
6 May 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
S-3
Shelf registration
28 Feb 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 286.50 mm | 286.50 mm | 286.50 mm | 286.50 mm | 286.50 mm | 286.50 mm |
Cash burn (monthly) | (no burn) | (no burn) | 19.68 mm | 16.86 mm | 12.56 mm | 13.61 mm |
Cash used (since last report) | n/a | n/a | 144.88 mm | 124.10 mm | 92.48 mm | 100.20 mm |
Cash remaining | n/a | n/a | 141.61 mm | 162.39 mm | 194.01 mm | 186.30 mm |
Runway (months of cash) | n/a | n/a | 7.2 | 9.6 | 15.4 | 13.7 |
Institutional ownership, Q4 2023
24.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 2 |
Closed positions | 100 |
Increased positions | 4 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 760.36 mm |
Total shares | 62.03 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
ARCH Venture Fund IX | 36.41 mm | $0.00 |
NEWTON (PTC) | 15.09 mm | $0.00 |
Foresite Capital Fund IV | 10.00 mm | $0.00 |
Mirae Asset Global Investments | 225.51 k | $437.48 mm |
SG Americas Securities | 99.22 k | $192.00 k |
Exchange Traded Concepts | 82.96 k | $160.94 mm |
Bleakley Financial | 48.11 k | $93.33 mm |
Arizona State Retirement System | 35.09 k | $68.07 mm |
China Universal Asset Management | 29.14 k | $57.00 k |
Nisa Investment Advisors | 153.00 | $297.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Feb 24 | Lang Matthew | Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 50,000 |
9 Feb 24 | Lang Matthew | Option Common Stock | Grant | Acquire A | No | No | 1.8 | 500,000 | 900.00 k | 500,000 |
9 Feb 24 | Stephen J. Hill | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 48,928 |
9 Feb 24 | Stephen J. Hill | Stock Option Common Stock | Grant | Acquire A | No | No | 1.8 | 400,000 | 720.00 k | 400,000 |
9 Feb 24 | Gary K. Lee | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 52,700 |
9 Feb 24 | Gary K. Lee | Stock Option Common Stock | Grant | Acquire A | No | No | 1.8 | 400,000 | 720.00 k | 400,000 |
9 Feb 24 | Charles W. Newton | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 48,729 |
9 Feb 24 | Charles W. Newton | Stock Option Common Stock | Grant | Acquire A | No | No | 1.8 | 400,000 | 720.00 k | 400,000 |
9 Feb 24 | Seely Lynn | Common Stock | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 200,000 |
News
HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $6 Price Target
7 May 24
Lyell Immunopharma Q1 Sales $3.000K Down From $65.000K YoY
6 May 24
Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
16 Apr 24
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
12 Apr 24
Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday
12 Apr 24
Press releases
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
7 May 24
Thinking about buying stock in Mediwound, AeroVironment, Airship AI, Lyell Immunopharma, or Sunshine Biopharma?
6 Mar 24
Thinking about buying stock in Intuitive Machines, Lyell Immunopharma, Hallador Energy, Eiger Biopharmaceuticals, or WEC Energy Group?
5 Mar 24